KemPharm (NASDAQ:KMPH) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.09, Fidelity Earnings reports.

Shares of NASDAQ:KMPH traded down $0.09 during midday trading on Wednesday, reaching $1.01. The company had a trading volume of 11,448 shares, compared to its average volume of 156,791. The company’s 50 day moving average is $1.46. The firm has a market capitalization of $32.80 million, a PE ratio of -0.41 and a beta of 1.39. KemPharm has a 1-year low of $1.00 and a 1-year high of $5.47.

KMPH has been the topic of several recent research reports. HC Wainwright initiated coverage on KemPharm in a research note on Wednesday, June 19th. They issued a “buy” rating and a $3.00 price target on the stock. Oppenheimer dropped their price target on KemPharm from $8.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, May 23rd. Finally, ValuEngine raised KemPharm from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. KemPharm presently has an average rating of “Buy” and an average price target of $5.50.

About KemPharm

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Recommended Story: Growth and Income Funds

Earnings History for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with's FREE daily email newsletter.